Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk.

Abstract

Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk- benefit analysis to determine what role pioglitazone should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed. This review provides a comprehensive overview of the present literature. Clinical data currently available indicate that pioglitazone is an effective and generally well-tolerated treatment option for use in patients with type 2 diabetes. Pioglitazone can still reduce adverse cardiovascular risk.

• Authors: Cong Zou, Honglin Hu
• Journal: Vascular health and risk management (Vasc Health Risk Manag) Vol. 9 Pg. 429-33 ( 2013) ISSN: 1178-2048 [Electronic] New Zealand
• PMID: 24023518 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Thiazolidinediones
• Pioglitazone

Topics

• Administration, Oral
• Cardiovascular Diseases (etiology, prevention & control)
• Diabetes Mellitus, Type 2 (complications, diagnosis, drug therapy)
• Humans
• Hypoglycemic Agents (administration & dosage, adverse effects)
• Patient Selection
• Pioglitazone
• Risk Assessment
• Risk Factors
• Thiazolidinediones (administration & dosage, adverse effects)
• Treatment Outcome